MPC 2130Alternative Names: MPC-2130
Latest Information Update: 26 Nov 2012
At a glance
- Originator Myriad Pharmaceuticals
- Developer Myrexis
- Mechanism of Action Apoptosis stimulants; Matrix metalloproteinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; Haematological malignancies